48
We have previously used the Cas9 Synergistic Activation Mediator (SAM) to screen for protein-49 coding genes that confer resistance to the BRAF inhibitor vemurafenib in melanoma cells 9 , 50 making this an ideal phenotype for screening lncRNA loci (Supplementary Note 1). We designed 51 a genome-scale sgRNA library targeting 10,504 intergenic lncRNA TSSs (see Methods, 52 Supplementary Table 1) 2,10
. We transduced A375 (BRAF(V600E)) melanoma cells with the 53 sgRNA library, cultured them in 2 μM vemurafenib or vehicle control for 14 days, and 54 sequenced the distribution of sgRNAs ( relevance of these loci to the screening phenotype (Extended Data Fig. 3a) . 64
Next, we turned to classifying the mechanisms by which activation of each of these loci 65 might lead to resistance, which could include (i) a non-local (trans) function of the lncRNA 66 transcript 5 , (ii) a local (cis) function of the lncRNA transcript or its transcription in affecting the 67 expression of a nearby gene 3, [6] [7] [8] ; (iii) a local function of the lncRNA promoter acting as a DNA 68 element (enhancer) 7, 8 ; and, in theory, (iv) a local function of SAM (Supplementary Note 2). To 69 study mechanisms that require the lncRNA or its transcription (i and ii above), we focused on the 70 6 of 11 loci where SAM targeting led to a robust lncRNA transcript upregulation (Fig. 1c,  71 Supplementary Table 3 ). The remaining 5 loci may function through a mechanism other than 72 activation of the lncRNA transcript (e.g., iii and iv above; Supplementary Note 3 and 73 Supplementary Table 4) . 74 We explored whether activating each of these 6 lncRNA loci might affect vemurafenib 75 resistance through non-local or local functions. To test whether candidate lncRNAs contribute to 76 vemurafenib resistance via non-local functions, we overexpressed cDNAs encoding each 77 lncRNA from randomly integrated lentivirus and did not find any that affected drug resistance 78 (Extended Data Fig. 3b ), suggesting that these loci likely do not act through non-local functions 79 (Supplementary Note 4 and Supplementary Table 3 ). To determine if the phenotype might result 80 instead from local functions of the lncRNA loci in regulating a nearby gene 3, 6, 7 , we examined the 81 expression of all genes within 1 Mb of the targeted sites. At 5 of the 6 loci, we found that SAM 82 targeting led to differential expression of between 1 and 8 nearby protein-coding genes 83 (Supplementary Table 4 ; for remaining locus, see Supplementary Note 5). For example, 84 activation of NR_109890 upregulated its neighboring gene EBF1 (Extended Data Fig. 3c ), and 85 activation of TCONS_00015940 led to dosage-dependent upregulation of 4 neighboring genes 86 (Fig. 2a,b) . Together, these analyses indicate that most candidate lncRNA loci appear to confer 87 vemurafenib resistance by regulating the expression of one or more nearby genes, including 88 some that have been previously implicated in vemurafenib resistance (e.g., EBF1, see 89
Supplementary mean ± SEM with n = 4. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. Expression of EMICERI and MOB3B upon tiling SAM across the EMICERI locus normalized to 277 a NT sgRNA. All values are mean ± SEM with n = 4. ****P < 0.0001; ***P < 0.001; **P < 278 0.01. ND = not detected. expression, and vemurafenib resistance in pAS clones. i to j, EMICERI and MOB3B expression 295 after ASO knockdown. Mean ± SEM, n = 4. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 296 lncRNA TSSs that were targeted with ~10 single guide RNAs (sgRNAs) each for a total library 306 of 95,958 sgRNAs. sgRNAs were designed to target the first 800 bp upstream of each TSS and 307 subsequently filtered for GC content >25%, minimal overlap of the target sequence, and 308 homopolymer stretch <4 bp. After filtering, the remaining sgRNAs were scored according to 309 predicted off-target matches as described previously 9 , and 6 sgRNAs with the best off-target 310 scores were selected in the first 200 bp region upstream of the TSS: 1 in the 200-300 bp region, 1 311 in the 300-400 bp region, 1 in the 400-600 bp region, and 1 in the 600-800 bp region. In regions 312 with an insufficient number of possible sgRNAs, sgRNAs were selected from the neighboring 313 region closer to the TSS. The ideal location for sgRNA targeting to achieve maximal activation, 314 either upstream or downstream of the TSS, may be unique for each lncRNA locus and dependent 315 on the local regulatory context (e.g., locations of TF binding sites). An additional 500 non-316 targeting sgRNAs were included as controls. Cloning of the SAM sgRNA libraries was 317 performed as previously described with a minimum representation of 100 transformed colonies to the sgRNA count and the counts were normalized to the total number of counts in the 361 condition. The sgRNA fold change as a result of screening selection was calculated by dividing 362 the normalized sgRNA counts in the vemurafenib condition by the control and taking the base 2 363 logarithm. RIGER 11 analysis was performed using GENE-E based on the normalized log 2 ratios 364 for each infection replicate. Since a low percentage of functional sgRNAs was expected for each 365 lncRNA loci, the weighted sum method was used. To determine the empirical false discovery 366 rate (FDR) of candidate lncRNA loci, the weighted sum for 10 randomly selected non-targeting 367 sgRNAs in the sgRNA library was used to estimate the P value for each lncRNA locus and a 368 threshold based on a FDR of 0.05 (Benjamini-Hochberg) was selected that corresponded to a P 369 value of 0.031. 7 candidate lncRNA loci were selected based on the average ranking between 370 infection replicates 1 and 2, and 9 candidate lncRNA loci were selected based on the average 371 ranking in all 4 infection replicates. All candidate lncRNA loci had P value < 10 Table  400 5), perturbing the EMICERI locus (Supplementary Table 7 Table 7 ) with command line options "--solexa-quals 448 --num-threads 8 --library-type fr-firststrand --transcriptome-max-hits 1 --prefilter-multihits --449 keep-fasta-order". To further investigate the mechanism for MOB3B overexpression, Ingenuity 450
Pathway Analysis was applied to all genes differentially expressed with at least 1.2-fold change 451 or less than 0.7-fold change and the most likely upstream regulator was reported. 452 453
Hi-C and chromatin immunoprecipitation with sequencing (ChIP-seq) in GM12878 454
In situ Hi-C data for GM12878 was obtained and visualized using 2.5kb-resolution KL-455 normalized observed matrix 23 . Hi-C data from 7 cell lines suggested similar topological domain 456 annotations as GM12878 23 , suggesting that the TAD present in GM12878 is consistent across 457 cell types. CTCF ChIP-seq for GM12878 and hg19 generated by the ENCODE Project 458 Consortium 24 was downloaded from UCSC Genome Browser. CTCF motifs were identified 459 using FIMO to search for the "V_CTCF_01" and "V_CTCF_02" position weight matrices from 460 TRANSFAC as described previously confirmed BRAF V600E melanoma cell models were be propagated for another 7-15 passages 528 and cryovial preserved. We used passage 12 cells for this study. All cells were refed every 3-4 529 days. 530
531

Gene expression and pharmacological validation analysis 532
Gene expression data (CCLE, TCGA) and pharmacological data (CCLE) were analyzed to better 533 understand the biological relevance of EMICERI and MOB3B. Transcript expression in TCGA 534
and CCLE samples was quantified as follows: 1) FASTQ files were generated from available 535 BAM files using SamToFastq in Picard Tools (https://broadinstitute.github.io/picard/); 2) reads 536 were aligned with STAR v2.5.2b using parameters from the GTEx Consortium pipeline 537 (https://github.com/broadinstitute/gtex-pipeline) and genome indexes generated for read lengths 538 of 48bp (TCGA) and 101bp (CCLE) (--sjdbOverhang option); 3) expression was quantified 539 using RSEM v1. condition. 24h after nucleofection, cells were selected for the sgRNA plasmid with 1 μg/mL 634 Puromycin (Thermo Fisher A1113803) for 2 days and changes in transcript expression were 635 determined by qPCR as described above. 636 637
Code availability 638
Code for lncRNA library design and the analyses described in this paper is available on Github 639 (https://github.com/fengzhanglab/LncRNA_Screen_Manuscript). Please note that the code is 640 published as is for reference. 641
642
Data availability 643
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